Transition considerations for extended half-life factor products
Gespeichert in:
| Veröffentlicht in: | Haemophilia : the official journal of the World Federation of Hemophilia 2015-05, Vol.21 (3), p.285-288 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 288 |
|---|---|
| container_issue | 3 |
| container_start_page | 285 |
| container_title | Haemophilia : the official journal of the World Federation of Hemophilia |
| container_volume | 21 |
| creator | Croteau, S. E. Neufeld, E. J. |
| description | |
| doi_str_mv | 10.1111/hae.12683 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2675256023</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2675256023</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4963-884437ed750d5afe0a928c9a2fc16a288b45488eb9841921a40a36a2f0fb58c33</originalsourceid><addsrcrecordid>eNp1kE1PAjEQhhujEUQP_gGziScPC_3e7k0gCCaoMcGPW1O6bVhcdrFdIvx7i3zcnMvMZJ55Z_ICcI1gG4XozJRpI8wFOQFNRDiLMUP8dFszFAuMeANceD-HEBEM-TloYCYYo4I2wf3EqdLndV6Vka5ClRmntp2PbOUis65NmZksmqnCxkVuTWSVrsNk6apspWt_Cc6sKry52ucWeHsYTPqjePwyfOx3x7GmKSexEJSSxGQJgxlT1kCVYqFTha1GXGEhpjQ8JMw0FRSlGCkKFQkDC-2UCU1IC9zudMPh75XxtZxXK1eGkxLzhGHGId5SdztKu8p7Z6xcunyh3EYiKLdeyeCV_PMqsDd7xdV0YbIjeTAnAJ0d8JMXZvO_khx1BwfJeLeR-9qsjxvKfUmekITJj-ehHNL3Xu-VfMon8gsstYEX</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2675256023</pqid></control><display><type>article</type><title>Transition considerations for extended half-life factor products</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Croteau, S. E. ; Neufeld, E. J.</creator><creatorcontrib>Croteau, S. E. ; Neufeld, E. J.</creatorcontrib><identifier>ISSN: 1351-8216</identifier><identifier>EISSN: 1365-2516</identifier><identifier>DOI: 10.1111/hae.12683</identifier><identifier>PMID: 25855484</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Blood Coagulation Factors - administration & dosage ; Blood Coagulation Factors - economics ; Blood Coagulation Factors - pharmacokinetics ; Factor IX - administration & dosage ; Factor IX - economics ; Factor IX - pharmacokinetics ; Factor VIII - administration & dosage ; Factor VIII - economics ; Factor VIII - pharmacokinetics ; Half-Life ; Hemophilia A - drug therapy ; Hemophilia B - drug therapy ; Humans</subject><ispartof>Haemophilia : the official journal of the World Federation of Hemophilia, 2015-05, Vol.21 (3), p.285-288</ispartof><rights>2015 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4963-884437ed750d5afe0a928c9a2fc16a288b45488eb9841921a40a36a2f0fb58c33</citedby><cites>FETCH-LOGICAL-c4963-884437ed750d5afe0a928c9a2fc16a288b45488eb9841921a40a36a2f0fb58c33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fhae.12683$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fhae.12683$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25855484$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Croteau, S. E.</creatorcontrib><creatorcontrib>Neufeld, E. J.</creatorcontrib><title>Transition considerations for extended half-life factor products</title><title>Haemophilia : the official journal of the World Federation of Hemophilia</title><addtitle>Haemophilia</addtitle><subject>Blood Coagulation Factors - administration & dosage</subject><subject>Blood Coagulation Factors - economics</subject><subject>Blood Coagulation Factors - pharmacokinetics</subject><subject>Factor IX - administration & dosage</subject><subject>Factor IX - economics</subject><subject>Factor IX - pharmacokinetics</subject><subject>Factor VIII - administration & dosage</subject><subject>Factor VIII - economics</subject><subject>Factor VIII - pharmacokinetics</subject><subject>Half-Life</subject><subject>Hemophilia A - drug therapy</subject><subject>Hemophilia B - drug therapy</subject><subject>Humans</subject><issn>1351-8216</issn><issn>1365-2516</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kE1PAjEQhhujEUQP_gGziScPC_3e7k0gCCaoMcGPW1O6bVhcdrFdIvx7i3zcnMvMZJ55Z_ICcI1gG4XozJRpI8wFOQFNRDiLMUP8dFszFAuMeANceD-HEBEM-TloYCYYo4I2wf3EqdLndV6Vka5ClRmntp2PbOUis65NmZksmqnCxkVuTWSVrsNk6apspWt_Cc6sKry52ucWeHsYTPqjePwyfOx3x7GmKSexEJSSxGQJgxlT1kCVYqFTha1GXGEhpjQ8JMw0FRSlGCkKFQkDC-2UCU1IC9zudMPh75XxtZxXK1eGkxLzhGHGId5SdztKu8p7Z6xcunyh3EYiKLdeyeCV_PMqsDd7xdV0YbIjeTAnAJ0d8JMXZvO_khx1BwfJeLeR-9qsjxvKfUmekITJj-ehHNL3Xu-VfMon8gsstYEX</recordid><startdate>201505</startdate><enddate>201505</enddate><creator>Croteau, S. E.</creator><creator>Neufeld, E. J.</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>201505</creationdate><title>Transition considerations for extended half-life factor products</title><author>Croteau, S. E. ; Neufeld, E. J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4963-884437ed750d5afe0a928c9a2fc16a288b45488eb9841921a40a36a2f0fb58c33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Blood Coagulation Factors - administration & dosage</topic><topic>Blood Coagulation Factors - economics</topic><topic>Blood Coagulation Factors - pharmacokinetics</topic><topic>Factor IX - administration & dosage</topic><topic>Factor IX - economics</topic><topic>Factor IX - pharmacokinetics</topic><topic>Factor VIII - administration & dosage</topic><topic>Factor VIII - economics</topic><topic>Factor VIII - pharmacokinetics</topic><topic>Half-Life</topic><topic>Hemophilia A - drug therapy</topic><topic>Hemophilia B - drug therapy</topic><topic>Humans</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Croteau, S. E.</creatorcontrib><creatorcontrib>Neufeld, E. J.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Haemophilia : the official journal of the World Federation of Hemophilia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Croteau, S. E.</au><au>Neufeld, E. J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Transition considerations for extended half-life factor products</atitle><jtitle>Haemophilia : the official journal of the World Federation of Hemophilia</jtitle><addtitle>Haemophilia</addtitle><date>2015-05</date><risdate>2015</risdate><volume>21</volume><issue>3</issue><spage>285</spage><epage>288</epage><pages>285-288</pages><issn>1351-8216</issn><eissn>1365-2516</eissn><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>25855484</pmid><doi>10.1111/hae.12683</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1351-8216 |
| ispartof | Haemophilia : the official journal of the World Federation of Hemophilia, 2015-05, Vol.21 (3), p.285-288 |
| issn | 1351-8216 1365-2516 |
| language | eng |
| recordid | cdi_proquest_journals_2675256023 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Blood Coagulation Factors - administration & dosage Blood Coagulation Factors - economics Blood Coagulation Factors - pharmacokinetics Factor IX - administration & dosage Factor IX - economics Factor IX - pharmacokinetics Factor VIII - administration & dosage Factor VIII - economics Factor VIII - pharmacokinetics Half-Life Hemophilia A - drug therapy Hemophilia B - drug therapy Humans |
| title | Transition considerations for extended half-life factor products |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T12%3A34%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Transition%20considerations%20for%20extended%20half-life%20factor%20products&rft.jtitle=Haemophilia%20:%20the%20official%20journal%20of%20the%20World%20Federation%20of%20Hemophilia&rft.au=Croteau,%20S.%20E.&rft.date=2015-05&rft.volume=21&rft.issue=3&rft.spage=285&rft.epage=288&rft.pages=285-288&rft.issn=1351-8216&rft.eissn=1365-2516&rft_id=info:doi/10.1111/hae.12683&rft_dat=%3Cproquest_cross%3E2675256023%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2675256023&rft_id=info:pmid/25855484&rfr_iscdi=true |